Eli Lilly and Company announced yesterday that they have terminated the Phase 2 trial of their BACE inhibitor LY2886721 due to liver abnormalities.
Despite ample evidence implicating Aβ in Alzheimer’s pathology, scientists still struggle to understand how the peptide harms the brain.
The FDA and EMA have endorsed a new tool for modeling AD clinical trials to select the best design, potentially speeding up drug discovery.
New research proposes a neuroimmune receptor as the latest Aβ binding partner.
The first report on PBB3, the latest tau ligand for brain imaging under development, suggests it binds all types of tau aggregate.
Rare mutations in the ADAM10 gene make a genetic case for the amyloid cascade as a cause of late onset Alzheimer's disease.
As NIH researchers are preparing to return to their laboratories, Alzheimer's researchers warn about the greater consequences of cutting already limited resources.
Functional neuroimaging scans can pick up stark neural abnormalities in football players with repeated head injuries before their cognition drops much in executive function tests.
An astrocyte protein stymies toxic interplay between Aβ oligomers and prion proteins.
People with neurodegeneration but not brain amyloid surface in two new studies of preclinical AD, suggesting this odd population is both legitimate and potentially large.
Changing ApoE levels in midlife influences Aβ pathology in mice, supporting an ApoE-oriented therapeutic strategy in Alzheimer’s disease.
Sleeping in an MRI scanner, babies with ApoE4 genotype reveal myelination and structural differences in brain areas affected in people with Alzheimer’s disease.
Allegations of falsified data embroil Japanese ADNI; project leaders respond that data corrections followed quality-control procedures.
Researchers identify a transcription factor that protects neurons during normal aging but goes AWOL in Alzheimer’s brains.
A single dose of a commonly prescribed antidepressant suppresses Aβ production in the human central nervous system.